Scarica l'app Stockscreener
9.47
0.64%
0.06
Dopo l'orario di chiusura:
9.47
Precedente Chiudi:
$9.41
Aprire:
$9.47
Volume 24 ore:
1.31M
Relative Volume:
0.41
Capitalizzazione di mercato:
$2.12B
Reddito:
$509.86M
Utile/perdita netta:
$165.35M
Rapporto P/E:
13.97
EPS:
0.6779
Flusso di cassa netto:
$107.55M
1 W Prestazione:
-4.34%
1M Prestazione:
+6.76%
6M Prestazione:
-41.14%
1 anno Prestazione:
-44.20%
Intervallo 1D:
$9.33
$9.49
Intervallo di 1 settimana:
$9.24
$10.05
Portata 52W:
$7.2101
$20.46
Adma Biologics Inc Stock (ADMA) Company Profile
Nome
Adma Biologics Inc
Settore
Industria
Telefono
(201) 478-5552
Indirizzo
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
9.47 | 2.19B | 509.86M | 165.35M | 107.55M | 0.6779 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-07-19 | Ripresa | Raymond James | Strong Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2021-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Iniziato | Jefferies | Buy |
| 2019-04-15 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-07 | Ripresa | H.C. Wainwright | Buy |
| 2017-12-11 | Reiterato | Maxim Group | Buy |
| 2017-11-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Aggiornamento | Maxim Group | Hold → Buy |
| 2016-08-01 | Downgrade | Maxim Group | Buy → Hold |
| 2016-07-25 | Reiterato | Maxim Group | Buy |
| 2015-05-13 | Reiterato | Maxim Group | Buy |
| 2014-12-08 | Iniziato | Oppenheimer | Outperform |
| 2014-12-01 | Reiterato | Maxim Group | Buy |
Mostra tutto
Adma Biologics Inc Borsa (ADMA) Ultime notizie
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Bank of America Corp DE Raises Holdings in ADMA Biologics Inc $ADMA - marketbeat.com
Why ADMA Biologics (ADMA) Is Up 5.6% After Reaffirming 2026 Revenue Guidance And EPS Momentum - Sahm
Behavioral Patterns of ADMA and Institutional Flows - Stock Traders Daily
ADMA|ADMA Biologics Inc|Price:9.410|Chg%:-0.370 - TradingKey
STATE STREET CORP Buys ADMA Biologics Inc (ADMA) -- Shares Look 49% Undervalued on GF Value - GuruFocus
Can Asceniv Help ADMA Stock Combat IG Market Challenges? - Yahoo Finance
ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds - Stocktwits
ADMA Biologics Inc (ADMA) Stock Forecasts - Yahoo Finance
ADMA Biologics: The Earnings Reset Still Leaves More Upside (NASDAQ:ADMA) - Seeking Alpha
Royal Bank of Canada Buys 759,984 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Janus Henderson Group PLC Trims Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA DEADLINEFINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of ADMA Biologics, Inc. to Contact the Firm Today! - ACCESS Newswire
ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, - GlobeNewswire
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - Voice of Alexandria
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action LawsuitContact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline - PR Newswire
ADMA Biologics Inc (ADMA): Investor Outlook Highlights 71.72% Potential Upside - DirectorsTalk Interviews
Robbins LLP Reminds ADMA Investors of the August 10, 2026 Lead Plaintiff Deadline; Contact the Firm for Information About Recovering Your Losses - PR Newswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026 - PR Newswire
BTU IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Peabody Energy Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BTU - GlobeNewswire Inc.
ADMA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts ADMA Biologics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biolog - The National Law Review
ADMA Biologics 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc.ADMA - ACCESS Newswire
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 - accessnewswire.com
ADMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ADMA Biologics 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ADMA Biologics, Inc.ADMA - businesswire.com
ADMA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ADMA Biologi - The National Law Review
ADMA 3-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors - GlobeNewswire
ADMA BIOLOGICS CLASS ACTION DEADLINE AUGUST 10th: Bragar - GlobeNewswire
MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
ADMA Shareholder Alert: August 10, 2026 Lead Plaintiff Deadline in ADMA Biologics, Inc. ... - Caledonian Record
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
ADMA Shareholder Alert: August 10, 2026 Lead Plaintiff - GlobeNewswire
MONDAY DEADLINE: Berger Montague Advises ADMA Biologics, Inc. (ADMA) Investors to Inquire About a Securities Fraud Class Action by August 10, 2026 - marketscreener.com
State Street (NASDAQ: ADMA) discloses 7.4% ADMA Biologics stake via SSGA advisers - Stock Titan
ADMA Biologics (ADMA) Receives a Buy from Canaccord Genuity - The Globe and Mail
$ADMA Court News: ADMA Biologics Securities Fraud Class - GlobeNewswire
First Trust Advisors LP Raises Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming DeadlinesADMA - PR Newswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ADMA Biologics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ADMA BIOLOGICS DEADLINE: ROSEN, THE FIRST FILING FIRM, - GlobeNewswire
ADMA Biologics (NASDAQ:ADMA) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness - The Globe and Mail
MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors - GlobeNewswire
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders - GlobeNewswire
ADMA Biologics (ADMA) Is Up 6.3% After Faster Net Income Growth Than Sales In Q2 2026 - simplywall.st
Adma Biologics Inc Azioni (ADMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):